Clinical Study of Herombopag Olamine Tablets Combined with rhTPO in the Treatment of Patients with Thrombocytopenia after Chemotherapy for Solid Tumor
Objective:To analyze the therapeutic effect of Herombopag Olamine Tablets+Recombinant Human Thrombopoietin(rhTPO)on patients with thrombocytopenia after chemotherapy for solid tumor.Method:A total of 88 patients with thrombocytopenia after chemotherapy for solid tumor in Jurong People Hospital from January 2022 to January 2023 were selected and divided into two groups according to random number table method,with 44 cases in each group.The control group was treated with rhTPO,and the observation group was treated with Herombopag Olamine Tablets on the basis of the control group,and both of them continued to be treated for 2 weeks.The clinical efficacy,platelet parameters,immune function and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was 95.45%(42/44),which was higher than 81.82%(36/44)in the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in platelet count(PLT),plateletcrit(PCT),mean platelet volume(MPV),platelet distribution width(PDW),CD3+,CD4+and CD8+between the two groups(P>0.05);after treatment,PLT was(136.97±10.63)×109/L,PCT was(0.20±0.07)%,CD3+was(54.38±6.25)%and CD4+was(48.39±5.40)%in the observation group,which were higher than(100.83±8.39)×109/L,(0.15±0.05)%,(49.75±5.42)%,(41.64±4.39)%in the control group,MPV was(13.21±2.20)fL,PDW was(15.20±2.58)%,CD8+was(24.26±1.58)%in the observation group,which were lower than(17.46±2.58)fL,(19.52±3.21)%,(28.71±2.26)%in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Herombopag Olamine Tablets+rhTPO can increase PLT and improve immune function in patients with thrombocytopenia after chemotherapy for solid tumor,and without serious adverse reactions.
万方数据
维普
